Vitamin D and Diabetes
Vitamin D receptors are expressed on pancreatic β-cells, and observational studies have long linked low serum 25(OH)D to insulin resistance and type 2 diabetes risk. The randomised evidence is more measured: supplementation helps prevent progression in some deficient prediabetic populations but does not clearly benefit those already sufficient.
Type 2 diabetes prevention
The definitive trial is D2d (Pittas et al., 2019): 2,423 US adults with prediabetes were randomised to 4,000 IU/day cholecalciferol or placebo for a median of 2.5 years. Overall, D3 supplementation did not reach statistical significance for progression to type 2 diabetes (HR 0.88; 95% CI 0.75–1.04). But in the pre-specified subgroup analysis of participants who reached ≥ 40 ng/mL serum 25(OH)D, risk fell substantially — hazard ratio ~0.24 versus placebo. The signal is real; the effect size depends heavily on achieving true sufficiency.
VITAL (Manson et al., 2019) — 25,000 adults, 5 years of 2,000 IU/day — found no reduction in incident type 2 diabetes in the general population. Bottom line: if you have prediabetes and low 25(OH)D, correcting it to 40+ ng/mL is a reasonable adjunct to lifestyle change; don't rely on vitamin D as a replacement for diet, exercise, or metformin.
Type 1 diabetes
Cohort studies from Finland, Norway, and the US show early-childhood vitamin D supplementation is associated with lower type 1 diabetes risk. The mechanism is immunomodulatory — vitamin D dampens the autoimmune destruction of β-cells. No randomised prevention trial has definitively confirmed this, but 400–1,000 IU/day in early childhood is safe and standard practice.
Insulin sensitivity and HbA1c
Meta-analyses of shorter trials in insulin-resistant patients show modest improvements in HOMA-IR and HbA1c with supplementation, primarily in vitamin-D–deficient participants. Effect sizes are small — typically 0.1–0.3 percentage points on HbA1c — but consistent enough to be worth pursuing correction of deficiency in patients with metabolic syndrome.
Gestational diabetes
Deficient pregnant women have ~1.5× the odds of gestational diabetes. Supplementation during pregnancy modestly reduces GDM incidence in deficient populations. See our pregnancy page for dosing.
Practical dosing for people with diabetes
- Test serum 25(OH)D at diagnosis if not recently done.
- Target ≥ 40 ng/mL — the level associated with the D2d subgroup benefit.
- Typical dose: 2,000–4,000 IU/day cholecalciferol for adults; adjust for weight (obese need more).
- Retest at 3 months to confirm you've reached target.
- Continue standard diabetes management — vitamin D is adjunct, not primary therapy.